SEC Tracker
Get the app

Lexeo Therapeutics LXEO

Lexeo Therapeutics files S-3 for $300M stock offering

Securities offering

Form
S-3
Filed
Importance
Routine
  1. $300,000,000 in common and preferred stock offered
  2. Includes $135,387,220.20 of unsold securities from prior S-3
  3. Prior registration statement filed on December 13, 2024
  4. Registration fee of $20,727.78 carried forward

Written from the S-3 on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Lexeo Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2836 and related industry codes: the same peer list as the financial tables.

  1. SELLAS Life Sciences Group SLS public float $219M, Jun 30, 2025
  2. Precigen PGEN public float $219M, Jun 30, 2025
  3. Perspective Therapeutics CATX public float $213M, Jun 30, 2025
  4. Rocket Pharmaceuticals RCKT public float $213M, Jun 30, 2025
  5. Natures Sunshine Products NATR public float $211M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.